Mode
Text Size
Log in / Sign up

Urinary Tract Infections

9 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Urinary Tract Infections

63 trials tracked for Urinary Tract Infections: 23 in phase 3 or 4 and 7 with published results. The most-cited published study has 111 citations.

63Trials tracked
23Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 9 Phase 3 14 Phase 2 13 Phase 1 5 Other / NA 22
  1. Phase 3 Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections Completed · 111 cited
  2. Phase 3 Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI) Completed · 82 cited
  3. Phase 3 A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI) Completed · 82 cited
  4. Phase 3 Corticosteroids for Children With Febrile Urinary Tract Infections Completed · 33 cited
  5. Phase 4 Effects of Antibiotic Prophylaxis on Recurrent UTI in Children Completed · 11 cited
  6. Phase 3 Chlorhexidine vs. Iodine for Vaginal Preparation in Urogynecologic Procedures Completed · 9 cited
Show 44 more trials
  1. Phase 3 Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women Completed · 8 cited
  2. Phase 4 A Bioequivalence Study of Cefadroxil Film Coated Tablets After A Single Oral Dose Administration to Healthy Subjects Completed
  3. Phase 4 A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL]) Completed
  4. Phase 4 Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection Completed
  5. Phase 4 Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults Completed
  6. Phase 4 Preventing Recurrent UTI With Vaginal Estrogen Completed
  7. Phase 4 A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections Completed
  8. Phase 4 Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI) Completed
  9. Phase 4 PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region Completed
  10. Phase 3 Prevention of Post-operative Urinary Retention Completed
  11. Phase 3 Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury Completed
  12. Phase 3 A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis) Completed
  13. Phase 3 A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis) Completed
  14. Phase 3 A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Completed
  15. Phase 3 Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055) Completed
  16. Phase 3 Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) Completed
  17. Phase 3 Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI) Completed
  18. Phase 2 Effectiveness of Preurodynamic With Posturodynamic Levofloxacin on the Incidence of UTI Completed
  19. Phase 2 Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion Completed
  20. Phase 2 Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy Completed
  21. Phase 2 Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Completed
  22. Phase 2 A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections Completed
  23. Phase 2 Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection Completed
  24. Phase 2 The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children" Completed
  25. Phase 2 Preventing Urinary Tract Infection Post-Surgery Completed
  26. Phase 2 Fecal Microbiota Transplantation (FMT) for MDRO UTI Completed
  27. Phase 2 Multifaceted Treatment of Catheter-related Urinary Tract Infection Completed
  28. Phase 2 Urinary Track Infection Prevention After Urogynecological Surgery Completed
  29. Phase 2 Effectiveness of Single Dose Fosfomycin and Single Dose Levofloxacin as Pre-urodynamic Antibiotic for UTI Prevention Completed
  30. Phase 2 Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003) Completed
  31. Phase 1 Colonizing Neurogenic Bladders With Benign Flora Completed
  32. Phase 1 Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections Completed
  33. Phase 1 Bacterial Interference for Prevention of Catheter-Associated UTI: Geriatric Pilot Study Completed
  34. Phase 1 Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants. Completed
  35. Phase 1 Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli Completed
  36. N/A Cefpodoxime vs Ciprofloxacin for Acute Cystitis Completed
  37. N/A Extended Spectrum Betalactamase Producing Bacteria; Epidemiology and Treatment in Non-hospitalized Patients Completed
  38. N/A Single Dose Monurol for Treatment of Acute Cystitis Completed
  39. N/A Cranberry for UTI Prevention in Residents of Long Term Care Facilities Completed
  40. N/A Comparative Study of Intermittent Catheters and Occurrence of Urinary Tract Infections Completed
  41. N/A Women's Improvement of Sexual Health (WISH) Demonstration Project Completed
  42. N/A Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection Completed
  43. N/A Laser Therapy for Treatment of Urogenital Symptoms in Women Completed
  44. N/A A Biochip for Rapid Diagnosis of Complicated Urinary Tract Infection Completed

Showing the 50 most-cited and recently-updated of 63 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about Urinary Tract Infections

Can a dipstick urinalysis reliably detect UTIs in babies under one year old?

Dipstick urinalysis has high specificity but low sensitivity for detecting UTIs in infants under 12 months, meaning it can rule in infection but often misses it.

Full answer →
How accurate is a dipstick test for UTI in febrile infants under 12 months?

A dipstick test is fairly accurate for UTI in febrile infants under 12 months, with high specificity (91-99%) but moderate sensitivity (60-90%), meaning it rules in infection well but may miss some cases.

Full answer →
What is the rate of breakthrough UTIs in children with VUR on antibiotics?

About 30.5% of children with VUR on antibiotic prophylaxis experience a breakthrough UTI, with higher risk in infants, high-grade reflux, and those with kidney scarring.

Full answer →
How common is fluoroquinolone resistance in community-acquired E. coli causing urinary tract infections in Mexico?

Fluoroquinolone resistance in community-acquired E. coli causing UTIs in Mexico is high, with studies showing up to 68% of isolates are ESBL-producing and associated with high resistance rates.

Full answer →
Does the FDA approved cefepime injection treat urinary tract infections in patients?

Yes, the FDA-approved cefepime injection is indicated for treating uncomplicated and complicated urinary tract infections caused by susceptible bacteria.

Full answer →
What is the global resistance rate for fluoroquinolones in E. coli causing urinary tract infections?

A 2025 meta-analysis found the global fluoroquinolone resistance rate in E. coli causing UTIs is about 31%, with ciprofloxacin resistance at 30%.

Full answer →
See all 6 questions about Urinary Tract Infections →